The PI3K/Akt signaling pathway represents one of the most critical pro-survival cascades in the central nervous system, regulating neuronal survival, metabolism, synaptic plasticity, and protein homeostasis[1]. Dysregulation of this pathway significantly contributes to neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and other neurodegenerative disorders[2]. The pathway serves as a crucial intersection between neurotrophic factor signaling and cellular survival mechanisms, making it a central focus for understanding neurodegeneration and developing therapeutic interventions[3].
Akt (also known as Protein Kinase B, PKB) is a serine/threonine protein kinase that promotes cell survival through multiple downstream effectors. The PI3K/Akt signaling cascade is one of the most important cell survival pathways in neurons, linking extracellular growth factor signals to intracellular survival programs. This pathway is particularly important in the central nervous system, where post-mitotic neurons require robust survival signaling to maintain function throughout the lifespan.
The class I PI3K isoforms are heterodimers consisting of a p85 regulatory subunit and a p110 catalytic subunit[4]:
PI3Kα (PIK3CA):
PI3Kβ (PIK3CB):
PI3Kγ (PIK3CG):
PI3Kδ (PIK3CD):
Akt exists in three isoforms with distinct tissue distributions[5]:
Akt1 (PKBα):
Akt2 (PKBβ):
Akt3 (PKBγ):
GSK-3β (Glycogen Synthase Kinase-3 Beta):
Akt phosphorylates GSK-3β at Ser9, inhibiting its kinase activity[6]. This provides a key link between PI3K/Akt signaling and tau phosphorylation. GSK-3β dysregulation contributes to both amyloid and tau pathology in AD. The kinase phosphorylates tau at multiple sites associated with NFT formation.
BAD (BCL2-Associated Agonist of Cell Death):
Akt phosphorylates BAD at Ser136, promoting its sequestration by 14-3-3 proteins[7]. This prevents BAD from inhibiting anti-apoptotic BCL-2 proteins. Neuronal survival requires BAD inactivation through phosphorylation.
FOXO Transcription Factors:
Akt phosphorylates FOXO1 and FOXO3a, promoting their cytoplasmic retention[8]. Phosphorylated FOXOs are sequestered in the cytoplasm by 14-3-3 proteins. This prevents transcription of pro-apoptotic genes including BIM, PUMA, and FasL.
mTOR (mammalian Target of Rapamycin):
Akt activates mTORC1 through multiple mechanisms including TSC2 inhibition and PRAS40 phosphorylation[9]. mTORC1 regulates protein synthesis through S6K1 and 4E-BP1. mTORC1 also inhibits autophagy, linking growth factor signaling to protein homeostasis.
CREB (cAMP Response Element-Binding Protein):
Akt can phosphorylate and activate CREB, promoting expression of survival genes[10]. CREB-mediated transcription is important for neuronal plasticity and memory. BDNF expression is partly regulated by CREB.
Multiple alterations in the PI3K/Akt pathway characterize Alzheimer's disease brain[11]:
Reduced Akt Signaling:
PTEN Upregulation:
Growth Factor Decline:
Amyloid-β Effects:
Amyloid-β (Aβ) impairs PI3K/Akt signaling through multiple mechanisms[12]:
Tau Pathology:
The relationship between PI3K/Akt and tau is complex[13]:
Synaptic Dysfunction:
PI3K/Akt critically regulates synaptic plasticity[14]:
Akt Activators:
Direct and indirect strategies to activate Akt are being explored[15]:
GSK-3 Inhibitors:
Targeting downstream GSK-3β offers therapeutic potential[16]:
mTOR Modulators:
mTOR inhibitors like rapamycin show neuroprotective effects[17]:
The PI3K/Akt pathway is particularly important for dopaminergic neuron survival[18]:
GDNF provides critical survival signaling for dopaminergic neurons[19]:
α-Synuclein pathology affects PI3K/Akt signaling[20]:
PI3K/Akt regulates mitochondrial function and dynamics[21]:
PI3K/Akt signaling alterations in ALS include[22]:
Mutant huntingtin affects PI3K/Akt signaling[23]:
The pathway affects oligodendrocyte survival and myelin repair[24]:
Akt activates mTORC1, which regulates autophagy[25]:
Modulating autophagy through PI3K/Akt has therapeutic potential[26]:
| Compound | Target | Status | Notes |
|---|---|---|---|
| GSK-3 inhibitors | GSK-3β | Clinical trials | AD, bipolar disorder |
| Rapamycin | mTORC1 | Approved | Immunosuppression, repurposed |
| Akt inhibitors | Akt | Clinical trials | Cancer applications |
| PI3K modulators | PI3K | Preclinical | Pathway modulation |
Multiple growth factor approaches target PI3K/Akt signaling[27]:
Viral vector-mediated gene delivery shows promise[28]:
Rational combinations are being developed:
PI3K/Akt pathway biomarkers under development[29]:
Genetic variations affecting pathway activity:
Emerging strategies include[30]:
The PI3K/Akt signaling pathway represents a central hub connecting neurotrophic factor signaling to neuronal survival, metabolic regulation, and protein homeostasis. Dysregulation of this pathway contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The pathway's importance is underscored by its multiple connections to key pathological features including amyloid-β toxicity, tau phosphorylation, α-synuclein aggregation, and mitochondrial dysfunction. Therapeutic strategies targeting this pathway, including growth factor therapies, GSK-3 inhibitors, and autophagy modulators, hold promise for disease-modifying treatments in neurodegeneration. Understanding the precise context of PI3K/Akt dysregulation in different neurodegenerative diseases will be essential for developing effective targeted therapies[31].
'AKT Signaling in Neurodegeneration: Opportunities and Challenges'. Molecular Neurobiology. 2024. ↩︎
'PI3K/AKT Pathway in Alzheimer''s Disease: From Molecular Mechanisms to Therapeutic Strategies'. Journal of Alzheimer's Disease. 2023. ↩︎
'AKT in Parkinson''s Disease: Focus on Neuronal Survival and Mitochondrial Function'. Neurobiology of Disease. 2022. ↩︎
Class I PI3K Isoforms in Neuronal Function. Cellular and Molecular Life Sciences. 2024. ↩︎
'AKT Isoforms in Brain: Distinct Functions'. Brain. 2024. ↩︎
GSK-3 in Tau Phosphorylation and Alzheimer's Disease. Neurobiology of Aging. 2023. ↩︎
BAD and Neuronal Apoptosis. Cell Death & Disease. 2023. ↩︎
FOXO Transcription Factors in Neuronal Survival. NeuroMolecular Medicine. 2009. ↩︎
mTOR and Autophagy in Neurodegeneration. Autophagy. 2024. ↩︎
'CREB and Memory: Synaptic Plasticity'. Trends in Neurosciences. 2000. ↩︎
AKT Phosphorylation in Alzheimer's Disease Brain. Journal of Neuropathology & Experimental Neurology. 2023. ↩︎
Amyloid-β Oligomers and Synaptic Dysfunction. Brain Pathology. 2008. ↩︎
Tau and PI3K/AKT Cross-talk. Neurobiology of Aging. 2024. ↩︎
PI3K/AKT Signaling in Synaptic Plasticity and Memory. Neurobiology of Learning and Memory. 2023. ↩︎
'AKT Activators: Chemical Biology and Therapeutic Potential'. Cell Chemical Biology. 2022. ↩︎
GSK-3 Inhibitors for Alzheimer's Disease. Expert Opinion on Therapeutic Targets. 2021. ↩︎
mTOR Inhibition in Parkinson's Disease Models. Nature Reviews Neurology. 2011. ↩︎
The Origins of Oxidative Stress in Dopaminergic Neurons. Nature Reviews Neuroscience. 2017. ↩︎
GDNF Signaling and Neuroprotection in Parkinson's Disease. Nature Reviews Neurology. 2019. ↩︎
α-Synuclein and PI3K/AKT Signaling in Parkinson's Disease. NPJ Parkinson's Disease. 2022. ↩︎
Mitochondrial AKT Signaling in Neurodegeneration. Mitochondrion. 2022. ↩︎
PI3K/AKT in Amyotrophic Lateral Sclerosis. Annals of Neurology. 2023. ↩︎
Huntington's Disease and PI3K/AKT Signaling Dysregulation. Brain. 2023. ↩︎
PI3K/AKT in Multiple Sclerosis. Nature Reviews Neurology. 2022. ↩︎
The Role of Autophagy in Neurodegeneration. Nature Medicine. 2003. ↩︎
Autophagy Induction as a Therapeutic Strategy. Nature Reviews Drug Discovery. 2022. ↩︎
Growth Factor Gene Therapy for Neurodegeneration. Molecular Therapy. 2023. ↩︎
AAV-Mediated Gene Therapy for Neurodegeneration. Human Gene Therapy. 2024. ↩︎
Biomarkers for PI3K/AKT Pathway Activity. Alzheimer's & Dementia. 2024. ↩︎
Therapeutic Targeting of PI3K/AKT Pathway in Neurodegeneration. Pharmacology & Therapeutics. 2023. ↩︎
'AMPK and PI3K/AKT: Energy Sensing Pathways'. Cell Metabolism. 2012. ↩︎